window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

clinical trial results

  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Olorofim meets primary endpoint in phase 3 OASIS aspergillosis study

    F2G and Shionogi have reported that oral olorofim met the [...]

    June 18, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics

    Ananda Pharma Phase 1 study of MRX1 shows safety and supports Phase 2 progression

    Ananda Pharma has reported positive results from its Phase 1 [...]

    June 18, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Oryzon reports strong early AML response data from iadademstat combinations at EHA 2026

    oryzon-iadademstat-aml-alice2-frida-eha-2026 Oryzon Genomics has reported updated Phase 1b data from [...]

    June 11, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA accepts Merck NDA for pimicotinib in tenosynovial giant cell tumor

    Merck has announced that the US Food and Drug Administration [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    AC Immune interim Phase 2 data suggest ACI-7104.056 may slow Parkinson’s disease progression

      AC Immune SA has reported positive interim results from [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Therapeutic Areas

    Gilead reports positive Phase 3 results for single-tablet HIV regimen

    Gilead Sciences has announced positive topline results from the Phase [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    EG 427 reports strong initial results for DNA therapy in neurogenic bladder trial

    EG 427 has released encouraging first clinical data from its [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development

    EC approves ADCETRIS-based BrECADD regimen for newly diagnosed advanced Hodgkin lymphoma

    Takeda’s antibody-drug conjugate gains second frontline indication following positive Phase [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Natus expands AI-powered EEG analysis across Europe
    Categories: Central Nervous System, Digital & Data, Medical devices
  • Enterome data link CD8 T-cell expansion to progression-free survival in lymphoma
    Categories: Advanced Therapies, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Telix starts Phase 3 trial of radiopharmaceutical therapy for renal cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top